HCWB — Hcw Biologics Income Statement
0.000.00%
- $8.57m
- $17.59m
- $2.57m
Annual income statement for Hcw Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.1 | 0 | 6.72 | 2.84 | 2.57 |
Cost of Revenue | |||||
Gross Profit | — | — | 2.59 | 0.56 | 0.959 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 9.92 | 12.8 | 21.8 | 28.6 | 32 |
Operating Profit | -5.82 | -12.8 | -15.1 | -25.7 | -29.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.8 | -12.9 | -14.9 | -25 | -30 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.8 | -12.9 | -14.9 | -25 | -30 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.8 | -12.9 | -14.9 | -25 | -30 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.07 | -12.9 | -14.9 | -25 | -30 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.94 | -15 | -16.6 | -27.8 | -30.4 |